CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

INTERMACS Profiles and Outcomes Among Non–Inotrope-Dependent Outpatients With Heart Failure and Reduced Ejection Fraction The effect of complete percutaneous revascularisation with and without intravascular ultrasound guidance in the drugeluting stent era Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial Impact of Lesion Preparation Strategies on Outcomes of Left Main PCI: The EXCEL Trial A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation) Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial A volumetric intravascular ultrasound comparison of early drug-eluting stent thrombosis versus restenosis Economic and Quality-of-Life Outcomes of Natriuretic Peptide–Guided Therapy for Heart Failure Considerations for Optimal Device Selection in Transcatheter Aortic Valve Replacement: A Review Sex differences in left main coronary artery stenting: Different characteristics but similar outcomes for women compared with men

Guidelinehttps://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehaa575/5898842

JOURNAL:Eur Heart J. Article Link

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)

J-P Collet, H Thiele, E Barbato et al. Keywords: ACS without persistent ST-segment elevation; Guidelines; acute cardiac care; angioplasty; anticoagulation; antiplatelet; apixaban; aspirin; atherothrombosis; betablockers; bleedings; bivalirudin; CABG; cangrelor; chest pain unit; clopidogrel; dabigatran; diabetes; DAPT; early invasive strategy; edoxaban; enoxaparin; fondaparinux; glycoprotein IIb/IIIa inhibitors; heparin; high-sensitivity troponin; MINOCA; myocardial ischaemia; MI; nitrates; platelet inhibition; prasugrel; revascularization; rhythm monitoring; rivaroxaban; stent; ticagrelor; triple therapy; unstable angina

Full Text PDF